Revance Therapeutics (RVNC) Tops Q1 EPS by 12c

Revance Therapeutics (NASDAQ: RVNC) reported Q1 EPS of ($0.71), $0.12 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $75 thousand versus the consensus estimate of $70 thousand.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• B.Riley on Nayax (NYAX): 'Sell-Off Overshoots the Story'
• Thor Industries (THO) Misses Q4 EPS by 13c